Literature DB >> 21795593

IL-22-induced regulatory CD11b+ APCs suppress experimental autoimmune uveitis.

Yan Ke1, Deming Sun, Guomin Jiang, Henry J Kaplan, Hui Shao.   

Abstract

We have previously reported that IL-17(+) interphotoreceptor retinoid-binding protein (IRBP) 161-180-specific T cells have a strong pathogenic effect in experimental autoimmune uveitis (EAU) induced in B10RIII mice; however, this pathogenic activity is not solely attributable to the major cytokine, IL-17, produced by these cells. To determine whether other cytokines produced by Th17 cells show a stronger association with their pathogenic activity, we studied the role of IL-22 in EAU. IL-22 is one of the major cytokines produced by these cells. Our results showed that administration of small doses of IL-22 to EAU-susceptible mice significantly reduced the severity of EAU. In addition, mice treated with IL-22 generated decreased numbers of IFN-γ(+) and IL-17(+) uveitogenic T cells, but increased numbers of Foxp3(+) regulatory T cells. Mechanistic studies showed that the effect of the injected IL-22 was on CD11b(+) APCs, which expressed increased levels of IL-22R during induction of disease following immunization with uveitogenic Ag. In vitro IL-22 treatment of CD11b(+) APCs collected from Ag-primed mice resulted in increased expression of programmed death ligand-1 and the production of increased amounts of IL-10 and TGF-β. Moreover, IL-22-treated CD11b(+) APCs caused IRBP161-180-specific T cells to lose their uveitogenic activity and acquire immunosuppressive activity, which suppressed the induction of EAU by additional pathogenic IRBP161-180-specific effector T cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21795593      PMCID: PMC3197698          DOI: 10.4049/jimmunol.1100482

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  40 in total

1.  IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia.

Authors:  Shean J Aujla; Yvonne R Chan; Mingquan Zheng; Mingjian Fei; David J Askew; Derek A Pociask; Todd A Reinhart; Florencia McAllister; Jennifer Edeal; Kristi Gaus; Shahid Husain; James L Kreindler; Patricia J Dubin; Joseph M Pilewski; Mike M Myerburg; Carol A Mason; Yoichiro Iwakura; Jay K Kolls
Journal:  Nat Med       Date:  2008-02-10       Impact factor: 53.440

2.  Retinal Astrocytes respond to IL-17 differently than Retinal Pigment Epithelial cells.

Authors:  Yan Ke; Guomin Jiang; Deming Sun; Henry J Kaplan; Hui Shao
Journal:  J Leukoc Biol       Date:  2009-08-18       Impact factor: 4.962

3.  Anti-inflammatory role of IL-17 in experimental autoimmune uveitis.

Authors:  Yan Ke; Ke Liu; Guo-Qiang Huang; Yan Cui; Henry J Kaplan; Hui Shao; Deming Sun
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

4.  Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-induced arthritis in C57BL/6 mice.

Authors:  Lies Geboes; Laure Dumoutier; Hilde Kelchtermans; Evelien Schurgers; Tania Mitera; Jean-Christophe Renauld; Patrick Matthys
Journal:  Arthritis Rheum       Date:  2009-02

5.  Linking genetic susceptibility to Crohn's disease with Th17 cell function: IL-22 serum levels are increased in Crohn's disease and correlate with disease activity and IL23R genotype status.

Authors:  Silke Schmechel; Astrid Konrad; Julia Diegelmann; Jürgen Glas; Martin Wetzke; Ekaterini Paschos; Peter Lohse; Burkhard Göke; Stephan Brand
Journal:  Inflamm Bowel Dis       Date:  2008-02       Impact factor: 5.325

6.  Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease.

Authors:  Lauren A Zenewicz; George D Yancopoulos; David M Valenzuela; Andrew J Murphy; Sean Stevens; Richard A Flavell
Journal:  Immunity       Date:  2008-12-19       Impact factor: 31.745

7.  Both Th1 and Th17 are immunopathogenic but differ in other key biological activities.

Authors:  Catherine A Cox; Guangpu Shi; Hongen Yin; Barbara P Vistica; Eric F Wawrousek; Chi-Chao Chan; Igal Gery
Journal:  J Immunol       Date:  2008-06-01       Impact factor: 5.422

8.  Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens.

Authors:  Yan Zheng; Patricia A Valdez; Dimitry M Danilenko; Yan Hu; Susan M Sa; Qian Gong; Alexander R Abbas; Zora Modrusan; Nico Ghilardi; Frederic J de Sauvage; Wenjun Ouyang
Journal:  Nat Med       Date:  2008-02-10       Impact factor: 53.440

9.  IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis.

Authors:  Katharina Kreymborg; Ruth Etzensperger; Laure Dumoutier; Stefan Haak; Angelita Rebollo; Thorsten Buch; Frank L Heppner; Jean-Christophe Renauld; Burkhard Becher
Journal:  J Immunol       Date:  2007-12-15       Impact factor: 5.422

10.  Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category.

Authors:  Dror Luger; Phyllis B Silver; Jun Tang; Daniel Cua; Zoe Chen; Yoichiro Iwakura; Edward P Bowman; Nicole M Sgambellone; Chi-Chao Chan; Rachel R Caspi
Journal:  J Exp Med       Date:  2008-04-07       Impact factor: 14.307

View more
  23 in total

1.  Long-term therapeutic effects of mesenchymal stem cells compared to dexamethasone on recurrent experimental autoimmune uveitis of rats.

Authors:  Lingjun Zhang; Hui Zheng; Hui Shao; Hong Nian; Yan Zhang; Lingling Bai; Chang Su; Xun Liu; Lijie Dong; Xiaorong Li; Xiaomin Zhang
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-08-14       Impact factor: 4.799

2.  The role of Th17-associated cytokines in the pathogenesis of experimental autoimmune uveitis (EAU).

Authors:  Deming Sun; Dongchun Liang; Henry J Kaplan; Hui Shao
Journal:  Cytokine       Date:  2015-03-02       Impact factor: 3.861

Review 3.  Cytokines in uveitis.

Authors:  Jessica E Weinstein; Kathryn L Pepple
Journal:  Curr Opin Ophthalmol       Date:  2018-05       Impact factor: 3.761

4.  Interleukin 22 ameliorates neuropathology and protects from central nervous system autoimmunity.

Authors:  Mary J Mattapallil; Jennifer L Kielczewski; Carlos R Zárate-Bladés; Anthony J St Leger; Kumarkrishna Raychaudhuri; Phyllis B Silver; Yingyos Jittayasothorn; Chi-Chao Chan; Rachel R Caspi
Journal:  J Autoimmun       Date:  2019-05-09       Impact factor: 7.094

Review 5.  Healing of intestinal inflammation by IL-22.

Authors:  Atsushi Mizoguchi
Journal:  Inflamm Bowel Dis       Date:  2012-02-22       Impact factor: 5.325

Review 6.  Emerging role of interleukin-22 in autoimmune diseases.

Authors:  Hai-Feng Pan; Xiang-Pei Li; Song Guo Zheng; Dong-Qing Ye
Journal:  Cytokine Growth Factor Rev       Date:  2012-08-18       Impact factor: 7.638

7.  The parasitic worm product ES-62 up-regulates IL-22 production by γδ T cells in the murine model of Collagen-Induced Arthritis.

Authors:  Margaret M Harnett; William Harnett; Miguel A Pineda
Journal:  Inflamm Cell Signal       Date:  2014

8.  Interleukin-22 reduces the severity of collagen-induced arthritis in association with increased levels of interleukin-10.

Authors:  Sujata Sarkar; Xiaoqun Zhou; Shivali Justa; Swaroopa Rani Bommireddy
Journal:  Arthritis Rheum       Date:  2013-04

9.  The multiple sclerosis risk gene IL22RA2 contributes to a more severe murine autoimmune neuroinflammation.

Authors:  H Laaksonen; A O Guerreiro-Cacais; M Z Adzemovic; R Parsa; M Zeitelhofer; M Jagodic; T Olsson
Journal:  Genes Immun       Date:  2014-07-10       Impact factor: 2.676

10.  AAV-IL-22 modifies liver chemokine activity and ameliorates portal inflammation in murine autoimmune cholangitis.

Authors:  Yu-Hsin Hsueh; Yun-Ning Chang; Chia-En Loh; M Eric Gershwin; Ya-Hui Chuang
Journal:  J Autoimmun       Date:  2015-11-01       Impact factor: 7.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.